Apr 14, 2021
In this episode, Brian E. Lacy, MD, PhD, joins
us to discuss the American College of Gastroenterology’s newest
guidelines for irritable bowel syndrome, options for patients with
IBS-D and IBS-C, and much more.
Brought to you by Red Hill Biopharma.
- Intro :02
- Can you briefly review the process that led to the final
- All recommendations are not created equal in this guideline or
any guideline … do you think that is a fair statement?
- Do you have some key takeaways for listeners in regards to the
diagnostic evaluation of patients with IBS?
- There’s always this debate about fecal calprotectin or fecal
lactoferrin or CRP … what do you do in your own practice?
- What do you want to tell the listeners in terms of testing to
adequately screen for Celiac disease in their patients with IBS
- Does it matter how you biopsy?
- What was your perspective on some of the new serologies for
- Can you review pelvic floor testing in patients with IBS and
what the listeners should be thinking about and what they should
- Do you see potentially IBS-D and IBS-C-specific guidelines
coming out in the future? 17:14
- Several commonly used therapies for IBS have weak
recommendations or recommendations against their use. Can you talk
about this or whether you use these therapies in your practice?
- What do you tell patients when they ask you about whether they
should get their stool analyzed or provide you with a report from
testing they’ve already done? 26:10
- Stool samples: are they even the best thing we should be
- What’s the proportion of patients that possibly or potentially
mismanaged getting colonoscopies, being started on expensive
medications, being started on probiotics and how do we shift from
this guideline and really getting this spread out in practice?
- The growing list of options for patients with IBS and
- Opinions on the available options for patients with IBS-D?
- Thank you again, Dr. Lacy 41:15
Brian E. Lacy, MD, PhD, is a board certified
gastroenterologist at the Mayo Clinic and the current co-editor in
chief of the American Journal of Gastroenterology. He is
the former editor in chief of Clinical and Translational
Gastroenterology and was the co-chairman for the Rome IV
Committee on Functional Bowel Disorders.
Disclosures: Berry, Chey and Lacy report no
relevant financial disclosures.
We’d love to hear from you! Send your comments/questions to Dr.
Berry and Dr. Chey at firstname.lastname@example.org.
Follow us on Twitter @HealioGastro @sameerkberry @umfoodoc